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Abstract Current technologies used to generate CRISPR/Cas gene perturbation reagents are
labor intense and require multiple ligation and cloning steps. Furthermore, increasing gRNA
sequence diversity negatively affects gRNA distribution, leading to libraries of heterogeneous
quality. Here, we present a rapid and cloning-free mutagenesis technology that can efficiently
generate covalently-closed-circular-synthesized (3Cs) CRISPR/Cas gRNA reagents and that
uncouples sequence diversity from sequence distribution. We demonstrate the fidelity and
performance of 3Cs reagents by tailored targeting of all human deubiquitinating enzymes (DUBs)
and identify their essentiality for cell fitness. To explore high-content screening, we aimed to
generate the largest up-to-date gRNA library that can be used to interrogate the coding and
noncoding human genome and simultaneously to identify genes, predicted promoter flanking
regions, transcription factors and CTCF binding sites that are linked to doxorubicin resistance. Our
3Cs technology enables fast and robust generation of bias-free gene perturbation libraries with yet
unmatched diversities and should be considered an alternative to established technologies.
DOI: https://doi.org/10.7554/eLife.42549.001
Introduction
CRISPR/Cas has rapidly become the gold standard for unbiased high-throughput experiments, out-
performing preexisting technologies such as RNAi (Evers et al., 2016; Morgens et al., 2016). A fun-
damentally important aspect of high-fidelity CRISPR/Cas screening is the quality of the gRNA library
that is interrogated, with its diversity and distribution primarily influencing downstream experimental
scales (Sanson et al., 2018). Conventionally used methods to generate gRNA libraries in pooled or
arrayed formats include T4 ligase or homology-based cloning techniques, which require the PCR-
based amplification of gRNA-encoding oligonucleotides as well as the presence of open plasmid
DNA for successful gRNA sequence cloning (Arakawa, 2016; Koike-Yusa et al., 2014; Ong et al.,
2017; Schmidt et al., 2015; Shalem et al., 2014; Vidigal and Ventura, 2015; Wang et al., 2014).
Owing to these technical constraints, conventional libraries contain an unwanted PCR and cloning-
dependent bias in their gRNA distribution that influences the experimental scale required for
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statistically significant hit calling (Shalem et al., 2014; Wang et al., 2014). CRISPR libraries have
become ubiquitously used in functional genomics efforts, underscoring relevance and utility of new
PCR- and cloning-free technologies.
The rod-shaped filamentous phage M13 differs from other bacteriophages in that its genome-
packaging capacity is variable and in that it is present as single-stranded (ss) DNA. Kunkel mutagen-
esis utilizes M13’s malleable coat and the ease of ssDNA purification from M13 phage and enables
rapid site-specific mutagenesis to construct high-quality phage display libraries (Handa and Var-
shney, 1998; Huang et al., 2012; Kunkel, 1985; Kunkel, 2001). Kunkel mutagenesis has signifi-
cantly contributed to the great success of phage display technologies (Ernst et al., 2013;
Sidhu, 2001).
Here, we demonstrate the applicability of Kunkel mutagenesis in the generation of high-quality
and high-fidelity CRISPR/Cas and RNAi gene perturbation reagents. In more detail, we developed a
highly reproducible improved Kunkel mutagenesis technology that is designed to generate 3Cs
CRISPR/Cas gRNA libraries robustly over a broad range of gRNA diversities. We demonstrate the
high fidelity of 3Cs gRNA libraries by targeting all human DUBs and then determining their prolifer-
ative depletion phenotype, confirming previously known and discovering hitherto unknown DUB
phenotypes. In an effort to enable unbiased screening within coding and noncoding regions, we
encoded SpCas9 nucleotide preferences into a degenerated oligonucleotide and generated a highly
complex CRISPR/Cas gRNA library (truly genome-wide (TGW)). Doxorubicin-positive selection
screens with the TGW library in unperturbed human telomerase-immortalized retinal pigmented epi-
thelial cells (hTERT-RPE1) were used to identify coding and noncoding regions, emphasizing the rel-
evance of noncoding sequence elements in drug-resistance mechanisms. To enable high-content
functional interrogations on a truly genome-wide scale, we introduce an optimized version of this
library (oTGW). In summary, we establish the 3Cs technology as a robust alternative method for the
generation of high-quality CRISPR/Cas gene perturbation libraries.
Results
Circular synthesized gRNAs are high-quality CRISPR/Cas reagents
In classical Kunkel mutagenesis (Kunkel, 1985; Kunkel, 2001), the circular ssDNA isolated from fila-
mentous phage is hybridized with a complementary oligonucleotide that is extended and ligated to
obtain a double-stranded DNA plasmid. As Kunkel mutagenesis is performed on ssDNA, we antici-
pated that it would be insensitive to the secondary DNA structures of viral sequence elements and
therefore should enable the PCR and cloning-free generation of lentiviral gene perturbation
reagents (Huang et al., 2012; Kunkel, 1985). We therefore hypothesized that the generation of len-
tiviral CRISPR/Cas gRNA libraries using circular ssDNA and Kunkel mutagenesis would reduce
the coupling of gRNA diversity to gRNA distribution and would generate reagents of high quality
(Figure 1A).
To demonstrate its general applicability to lentiviral CRISPR/Cas plasmids, we transformed
Escherichia coli CJ236 bacteria with the commonly used pLentiGuide and pLentiCRISPRv2 plasmids
(Sanjana et al., 2014), both of which contain a U6 promoter-controlled non-human targeting (NHT)
placeholder gRNA followed by a SpCas9 tracrRNA sequence (Doench et al., 2014; Sanjana et al.,
2014). Importantly, F-factor-containing CJ236 bacteria lack dUTPase (dut–) and uracil-glycosylase
(ung–), and therefore tolerate the presence of deoxyuridine (dU) in genomic and plasmid DNA
(Kim and Wilson, 2012). Superinfection of single-colony CJ236 culture with M13KO7 bacteriophage
(108 cfu/mL) facilitated the generation of >30 mg of dU-containing circular ssDNA. Although circular
ssDNA is identical in length to dsDNA, the circular ssDNA of lentiviral CRISPR/Cas plasmids
migrated faster and appeared as a single band in gel electrophoresis (Figure 1B). Circular dU-
ssDNA was hybridized with a gRNA-encoding complementary oligonucleotide that contained
sequence homology regions (3Cs homology) at its 50 and 30 ends, and then extended and ligated
with T7 polymerase and T4 ligase, respectively (Figure 1A). This resulted in heteroduplexed 3Cs
DNA (3Cs-dsDNA), which were composed of dU-template ssDNA and deoxythymidine-containing
newly synthesized complementary DNA that also includes the gRNA-encoding oligonucleotide
(Figure 1A) (Huang et al., 2012; Kunkel, 1985; Kunkel, 2001). To gain insights into
the oligonucleotide requirements and kinetics of 3Cs reactions, we tested different 3Cs homology
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Figure 1. The 3Cs technology - covalently-closed-circular-synthesized (3Cs) CRISPR/Cas gRNA reagents. (A) The general 3Cs workflow. The individual
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Figure 1 continued on next page
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lengths of 10, 13, 15, and 18 nucleotides, performed a 3Cs reaction time series, and
demonstrated that 18 nucleotides of homology (above 45˚C annealing temperature) and 2 hr of 3Cs
reaction time were sufficient (Figure 1—figure supplement 1A–C) (Kunkel, 2001).
Using rule set 2 (RS2) (Doench et al., 2014, Doench et al., 2016), we designed six GFP-targeting
gRNA sequences and extended them by 50 and 30 3Cs homology. Synthesized gRNA-encoding oli-
gonucleotides were hand-pooled in equimolar ratios, phosphorylated and used in a 1:5 ratio (2 mg
ssDNA to 60 ng oligonucleotide) to generate heteroduplex dU-3Cs-sDNA (Figure 1C). To remove
NHT/dU-containing template and to amplify the gRNA-encoding complementary strand, 3Cs prod-
ucts were column-purified and transformed in dut+/ung+ bacteria. Bacterial clones were grown and
their plasmid DNA Sanger sequenced, revealing that 81% of pLentiGuide and 82% of plenti-
CRISPRv2 contained GFP-targeting gRNAs (Figure 1D and Figure 1—figure supplement 1D). To
test whether dU supplementation reduces the amount of NHT-containing template plasmid by
improving dU-incorporation during ssDNA production, CJ236 culture medium was supplemented
with 2.5 mM dU. In addition, the gRNA placeholder sequence of pLentiGuide and plentiCRISPRv2
was changed to contain an I-SceI restriction enzyme recognition site. Although the effect of
increased dU concentrations was negligible, I-SceI-mediated removal of wildtype plasmids reduced
their level to below our detection limit (Figure 1D and Figure 1—figure supplement 1D–F). We
performed next-generation sequencing (NGS) on the plentiCRISPRv2 sample with an average read
count of 1.15 million per GFP sequence and identified a wildtype rate of below 0.3% in the absence
of any apparent sequence bias (Figure 1E and Supplementary file 1). A one-sided Chi-squared test
for goodness of fit identified a uniform distribution (p=0.1) of all six gRNA sequences. The uniform
gRNA distribution was supported by a low coefficient of variation (CV) of 33.18% and an area under
the curve (AUC, Lorenz curve) of only 0.56 (Figure 1E–F and Figure 1—figure supplement 1G).
To test for the cellular functionality of 3Cs gRNAs, we used the plentiCRISPRv2 GFP-targeting
3Cs gRNA constructs to generate infectious lentiviral particles and transduced GFP-positive human
telomerase-immortalized retinal pigmented epithelial (hTERT–RPE1) cells. Seven days post-transduc-
tion, we performed a T7 Endonuclease I assay and observed robust GFP gene editing, both by a sin-
gle GFP-targeting 3Cs gRNA (3Cs-gRNA) and by the pool of six 3Cs-gRNAs, whereas un-transduced
Figure 1 continued
In more detail, f1-origin containing double-stranded CRISPR/Cas plasmids are converted to dU-containing circular ssDNA. Guide RNA sequence
(orange triangle) containing oligonucleotides (orange arrows) are annealed to ssDNA, and extended and ligated by T7 DNA polymerase and T4
ligase, respectively. Heteroduplex dU-3Cs-DNA is transformed into base-excision-repair-sufficient bacteria to deplete template DNA (grey strand) and
to amplify the newly synthesized DNA (orange) selectively. (B) Lentiviral CRISPR/Cas plasmids (pLentiGuide, pLentiCRISPRv2) and the mammalian cDNA
expression plasmid pcDNA3 (positive control) were converted to dU-containing circular ssDNA and analyzed by gel electrophoresis. Although identical
in size, circular ssDNA appears as a single band and migrates faster than the corresponding dsDNA form. (C) The lentiviral circular ssDNA of panel (B)
was annealed with a pool of six oligonucleotides, encoding six GFP-targeting gRNAs, to generate a pool of 3Cs-dsDNA and analyzed by gel
electrophoresis. A successful 3Cs in vitro reaction is indicated by three distinct 3Cs-dsDNA product bands (Huang et al., 2012). (D) Bar graph showing
the degree of template remnants in the final 3Cs products in the presence and absence of additional Uridine in the phage culture medium as well as an
I-SceI clean-up step. The gRNA libraries from panel (C) were sequenced by NGS before and after I-SceI restriction enzyme digest. Although the effect
of Uridine is marginal, an enzymatic digest with I-SceI removes template plasmid remnants. (E, F) gRNA distribution displayed as raw read count data
points (E) and normalized values in box plot format (F). The coefficient of variation was calculated by dividing the standard deviation by the mean of the
library’s read counts and is displayed as percentage above the box plot (F). Data were derived from the NGS data shown in panel (D). The final GFP-
targeting 3Cs-gRNA library is free of sequence bias, as demonstrated by the low coefficient of variation of 33.18%, and by the uniform sequence
distribution ((E), also see Figure 1—figure supplement 1H). (G) GFP-expressing hTERT–RPE1 cells were transduced with lentiviral 3Cs-gRNA constructs
(non-targeting control gRNA (non-human target sequences (NHT)), a single GFP-targeting 3Cs-gRNA (GFP#1) or a pool of six GFP-targeting 3Cs-
gRNAs (GFP#1–6)), and selected with puromycin before GFP gene editing was analyzed by T7 endonuclease I assay (Guschin et al., 2010). Individual
band intensities were quantified (black numbers). An empty control (–) served as the reference. (H) A dose-dependent reduction of GFP fluorescence
was determined by the flow cytometry of GFP-expressing hTERT–RPE1 cells and transduced with increasing volumes of lentiviral supernatant containing
a pool of six GFP-targeting 3Cs-gRNAs (GFP#1–6). Error bars represent standard deviations (SDs) over three biological replicates (n = 3). (I) Immunoblot
analysis of hTERT–REP1 cells treated as in panel (G) demonstrates that GFP-targeting 3Cs-gRNAs induce a 3- to 4-fold reduction in total GFP protein
levels over three biological replicates (n = 3, for quantification see also Figure 1—figure supplement 1I).
DOI: https://doi.org/10.7554/eLife.42549.002
The following figure supplement is available for figure 1:
Figure supplement 1. Determining 3Cs parameters, I-SceI template remnant removal, and the GFP library.
DOI: https://doi.org/10.7554/eLife.42549.003
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(–) and an NHT control gRNA failed to edit the GFP gene (Figure 1G). GFP gene editing translated
to a lentiviral dose-dependent loss of GFP protein when analyzed by fluorescence flow-cytometry
and immunoblotting (Figure 1H–I and Figure 1—figure supplement 1H). Taken together, we dem-
onstrate that the 3Cs technology enables the rapid and cloning-free generation of high-quality single
and pooled CRISPR/Cas gRNAs.
3Cs uncouples sequence diversity from sequence distribution
The absence of PCR amplification and cloning steps, in combination with the uniform distribution of
the six GFP-targeting 3Cs-gRNAs, led us to reason that 3Cs may uncouple sequence diversity from
sequence distribution during gRNA library generation. To test this hypothesis, we designed six
degenerated 3Cs oligonucleotides with increasing numbers of randomized nucleotides to mimic
gRNA sequence pools with diversities ranging from 256 to 262,144 individual sequences
(Figure 2A). The six pools were applied in parallel 3Cs syntheses on a dU-ssDNA template of pLenti-
CRISPRv2 (Figure 2B and Figure 2—figure supplement 1A). Independent of an oligonucleotide’s
diversity, NGS and computational analyses identified all of the individual sequences and uniform dis-
tributions with area under the curve values between 0.6 and 0.73 (Figure 2—figure supplement 1B
and Supplementary file 2). Despite the uniform distribution, we observed a prominent cytosine (C)
bias in the randomized libraries, with C contents of above 40% within the top 10% of the most abun-
dant gRNAs (Figure 2C). We reasoned that the C bias is probably due to incomplete phosphorami-
dite mixing during oligonucleotide synthesis and should therefore be absent from gRNA libraries
containing nonrandom gRNA sequences (Ellington and Pollard, 2009). To test this hypothesis, we
designed and generated a nonrandom 3Cs-gRNA library targeting all 105 human DUBs, each with
three gRNAs (DUB library). NGS and nucleotide content analysis confirmed our hypothesis and
revealed the absence of C bias from the nonrandom DUB library (Figure 2C and
Supplementary file 3). To correct the randomized libraries for the C bias, we determined the indi-
vidual nucleotide frequency at every randomized position and used these frequencies to normalize
the original read counts, leading to improved AUC values and sequence distributions (Figure 2D
and Supplementary file 2) and further confirming the uncoupling of sequence diversity and distribu-
tion in 3Cs reactions. Taken together, these findings lead us to conclude that 3Cs is a robust tech-
nology that uncouples sequence distribution from sequence diversity and, therefore, is a powerful
alternative technology to conventional gRNA cloning methods for generating gRNA libraries.
3Cs-gRNA libraries are of high fidelity: the proliferative essentiality of
human DUBs
Next, we investigated the performance of 3Cs-gRNA reagents in cellular screenings. To do so, we
generated infectious lentiviral particles of the 3Cs-gRNA DUB library and applied them to a prolifer-
ation screen in non-transformed hTERT–RPE1 cells in biological duplicates (multiplicity of
infection (MOI) 0.2, coverage 1,000). Two days after lentiviral transduction, cells were either col-
lected (day 0, reference time point) or selected by puromycin and kept in culture for 11 days (day
11) or 21 days (day 21) in cycling conditions representing at least a 1,000-fold library coverage
(Figure 3A). Cells collected at day 0, 11, or 21 were subjected to genomic DNA extraction and
amplicon-based NGS library preparation, as has been reported previously (Doench et al., 2016;
Koike-Yusa et al., 2014). We performed single-read sequencing on an Illumina NextSeq500 with an
averaged read count per gRNA of above 35,000 across all biological samples and replicates
(Supplementary file 4). As in previously reported CRISPR analysis algorithms, and to enable a com-
parison of individual time points, we summed all individual gRNA read counts per gene and normal-
ized each gene read count per sample to the total number of read counts within that sample
(Supplementary file 4) (Li et al., 2014; Spahn et al., 2017). In line with reports of the high experi-
mental reproducibility of CRISPR/Cas screenings (Evers et al., 2016; Morgens et al., 2016), we
determined R2 values of 0.95, 0.88, and 0.90 for time points day 0, 11, and 21, respectively (Fig-
ure 3—figure supplement 3A–C). Spearman correlation and Shapiro–Wilk confidence tests revealed
correlations of above 0.88 and p-values of below 0.001, respectively, demonstrating a high experi-
mental confidence in the level of gRNA representation (Figure 3B and Figure 3—figure supple-
ment 3A–C) (Shapiro and Wilk, 1965). To analyze the reproducibility of our screen in terms of the
level of gene phenotypes, we applied MAGeCK and PinAPL-Py, two established algorithms for the
Wegner et al. eLife 2019;8:e42549. DOI: https://doi.org/10.7554/eLife.42549 5 of 31
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Figure 2. 3Cs is a robust technology that uncouples sequence diversity from sequence distribution. (A) To determine the sequence distribution of 3Cs-
gRNA libraries with increasing gRNA diversity, an increasing number of randomized nucleotides (orange) were incorporated into 3Cs oligonucleotides
to mimic gRNA diversities ranging from 256 to 262,144 sequences (4–9N libraries). A range of four to nine randomized nucleotides (orange) were
introduced into an NHT gRNA sequence. Randomization of the central nucleotides ensures the replacement of the template I-SceI restriction site
in order to prevent the digestion of correctly synthesized 3Cs synthesis products. (B) The 3Cs synthesis products of the combination of randomized
primers and pLentiGuide were resolved by gel electrophoresis. (C) The Scatter plot displays ranked gRNA abundances per library against the gRNA
cytosine content (C). The gRNA libraries that are shown are derived from (A) and (B) and the library with gRNAs targeted against DUBs (DUBs library).
All libraries were processed by I-SceI-dependent removal of template plasmid remnants and subjected to NGS and computational analysis.
Importantly, all gRNA libraries were complete, irrespective of their individual gRNA diversity. However, the partially randomized gRNA libraries
displayed a strong C bias within the most abundant gRNA sequences. In fact, the top 5% of most abundant gRNAs had a C content of above 60%. The
DUBs library did not show this C bias, strongly suggesting incomplete phosphoramidite mixing during oligonucleotide synthesis as the main cause of
the C bias. (D) Lorenz curves displaying the cumulative fraction of represented NGS reads versus the gRNAs ranked by abundance of each partially
randomized (4–9N) and nonrandomized (DUB) library revealed a uniform distribution of gRNA sequences. Area under the curve values (AUC, number
next to library name) confirm the uniform gRNA distribution of these libraries and demonstrate that 3Cs uncouples sequence diversity from sequence
distribution.
DOI: https://doi.org/10.7554/eLife.42549.004
Figure 2 continued on next page
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analysis of CRISPR/Cas screens, to raw gRNA read counts of both replicates and calculated aggre-
gated positive and negative proliferation phenotypes by means of log2-fold changes with associated
p-values (Figure 3C–E and Figure 3—figure supplement 3D–H and Supplementary file 5–
6) (Li et al., 2014; Spahn et al., 2017). Consistent over both time points, cells depleted of USP28 or
BRCC3 proliferated more rapidly than cells harboring non-human target sequences (NHTs), identify-
ing both as negative regulators of hTERT–RPE1 proliferation (Figure 3C–D and Figure 3F and
Supplementary file 4–5). By contrast, cells that were depleted of PSMD14, USP7 or COPS6 prolifer-
ated less rapidly than cells harboring non-human target sequences (NHTs), identifying them as posi-
tive regulators of hTERT–RPE1 proliferation (Figure 3C–D and Figure 3F and Supplementary file
4–5).
CRISPR/Cas drop out screens are performed with varying experimental durations, ranging from 5
to 15 days (Joung et al., 2017; Potting et al., 2018). However, recent work demonstrates that
CRISPR/Cas induces a G1 phase arrest in p53 proficient hTERT–RPE1 cells that impacts hit calling
(Haapaniemi et al., 2018), suggesting that later screening time points are beneficial for hit calling.
Indeed, when comparing normalized gene ranks, we observed a trend of increased phenotype reso-
lution among negative gene ranks over time, although this effect was largely absent from positive
gene ranks (Figure 3—figure supplement 1I and Figure 3—figure supplement 2 and 3). This effect
has been reported previously and can potentially be explained by the disproportional assay window
of positive and negative cell proliferation phenotypes, leading to a higher phenotypic resolution
among negative proliferative effects (Shalem et al., 2014; Wang et al., 2014).
Stable and robust proliferative phenotypes are time-independent, so the phenotype resolution
enhances over time (Figure 3—figure supplement 3I). However, multiple mechanisms and cellular
backgrounds can influence phenotype strength, timing and orientation. To identify time-dependent
phenotypes, we analyzed the MAGeCK-derived log2-fold changes with associated p-values for time
points day 11 and day 21, and identified genes whose deletion phenotype significantly changed
between day 11 and day 21 (Figure 3E–F). Depletion of USP28 and USP46 induced the strongest
positive change, whereas deletion of USP22, USP48 or TNFAIP3 induced the most significant nega-
tive change, in phenotype between day 11 and day 21, suggesting a time-dependent absence of
compensatory mechanisms to accommodate an early loss-of-function phenotype (Figure 3E–F and
Figure 3—figure supplement 3I). In order to validate our findings, we chose two positive and nega-
tive proliferation-inducing DUBs, generated lentiviral supernatant to deliver shRNA sequences tar-
geting the selected DUBs, and transduced hTERT–RPE1 cells. Over the course of the 2 weeks after
transduction, we measured cell numbers by AlamarBlue staining. When compared to negative-
(Luciferase) and positive-control (Plk1) shRNA sequences, depletion of USP28 and BRCC3 induced a
rapid positive proliferation effect (Figure 3G). By contrast, depletion of USP7 and COPS6 induced
an instant and strong negative proliferation effect (Figure 3G), validating the gRNA-mediated
knockout phenotypes. Collectively, our analysis demonstrates the quality and fidelity of 3Cs reagents
in functional genomics applications.
3Cs is versatile and generates arrayed and pooled 3Cs-shRNA reagents
Owing to its versatility,CRISPR/Cas technology has become the method of choice for gene perturba-
tion experiments, yet classical short hairpin RNAs (shRNA, RNAi) are still widely used. However,
shRNA oligonucleotides contain complementary sequences that form stable secondary structures
that render the generation of shRNA reagents inefficient (McIntyre and Fanning, 2006). A crucial
step in our improved Kunkel mutagenesis technology is the denaturation of the gRNA-encoding oli-
gonucleotides and their subsequent annealing to template ssDNA (see ’Materials and methods’ sec-
tion). Owing to this denaturation and annealing step, we anticipated that improved Kunkel
mutagenesis would circumvent the secondary structures of shRNA oligonucleotide and enable the
generation of shRNA reagents. We chose pLKO.1 (Stewart et al., 2003), one of the most widely
Figure 2 continued
The following figure supplement is available for figure 2:
Figure supplement 1. Quality control and gRNA distributions of the randomized libraries.
DOI: https://doi.org/10.7554/eLife.42549.005
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Figure 3. 3Cs reagents are of high fidelity — the essentiality of human DUBs for cell fitness. (A) Schematic of the performed CRISPR screen.
Highlighted are the experimental conditions under which the screen was performed (MOI of 0.2, library coverage of 1,000). In brief, hTERT–RPE1 cells
were transduced with lentivirus for 48 hr in duplicates, after which the cells of one duplicate were harvested (day 0) to extrapolate the baseline gRNA
distribution. Simultaneously, cells of the second duplicate were subject to puromycin selection for 11 days, after which time all cells were harvested (day
11), counted and plated back in low density to the original library representation of 1,000-fold coverage. Plated cells remained in cycling conditions
until day 21, when all cells were collected (day 21). After harvesting the cells, their genomic DNA was extracted and processed for gRNA NGS. (B)
Graph showing the distribution of individual sgRNAs. Means ± standard deviation are highlighted. (C–E) Volcano plots visualizing log2-fold changes of
gene phenotypes and their associated p-values. Data are derived from MAGeCK analyses, corresponding to day 11 (C), day 21 (D) and day11/21 (E).
The dashed red line shows p=0.05 with points above the line having p<0.05 and points below the line having p>0.05. Data points with p>0.05 are
displayed as translucent symbols. Genes of interest are highlighted. (F) Venn diagram of significantly enriched (blue) or depleted (orange) DUBs. The
time point overlap visualizes DUB genes with time independent (overlap of three) and time dependent (overlap of two) proliferation phenotypes. (G)
Fold increase in cell number after shRNA-mediated depletion of target genes. Data are means of duplicates.
DOI: https://doi.org/10.7554/eLife.42549.006
The following figure supplements are available for figure 3:
Figure supplement 1 The 3Cs DUB gRNA screens are highly reproducible.
DOI: https://doi.org/10.7554/eLife.42549.007
Figure 3 continued on next page
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used lentiviral and shRNA-expressing plasmids to generate circular dU-ssDNA. Similar to circular
ssDNA of CRISPR/Cas plasmids, the circular ssDNA of pLKO.1 migrated as a single band in agarose
gel electrophoresis (Figure 3—figure supplement 2A). Next, we designed a GFP-targeting 3Cs
shRNA (3Cs-shRNA) primer consisting of 50 and 30 3Cs homology and two complementary GFP–
shRNA sequences separated by a six-nucleotide hairpin sequence (Figure 3—figure supplement
2B). We performed two parallel 3Cs reactions using 60 ng and 120 ng of ssDNA, and both reactions
yielded the characteristic 3Cs-DNA band pattern with no major difference in bacterial transformation
efficiency between the two tested scales (Figure 3—figure supplement 2C).
To demonstrate the successful integration of the GFP–shRNA sequence into pLKO.1, we ampli-
fied single bacterial clones carrying 3Cs-DNA of shRNA reactions and analyzed their plasmid DNA
by SANGER sequencing. This resulted in the expected GFP–shRNA sequence and the absence of
adjacent nucleotide changes (Figure 3—figure supplement 2D), from which we concluded that 3Cs
is a versatile technology that generates high-quality gRNA and shRNA reagents. To demonstrate
3Cs-shRNA fidelity, we generated infectious lentiviral particles of the GFP-targeting 3Cs-shRNA and
transduced GFP-positive hTERT–RPE1 cells. Strikingly, 96 hr after lentiviral transduction, we
observed a reduction in GFP-fluorescence, confirming the functionality of the 3Cs-shRNAs in cells
(Figure 3—figure supplement 2E). Moreover, we investigated the performance of improved Kunkel
mutagenesis in generating 3Cs-shRNA libraries. On the basis of the principles described above, we
designed a 3Cs-shRNA library targeting all human ubiquitin-conjugating E2 enzymes (E2s), each with
two shRNAs (Supplementary file 7). To generate the library, individually synthesized oligonucleoti-
des were pooled in equimolar ratios and applied to a pooled 3Cs reaction. The resulting products
were resolved by gel electrophoresis (Figure 3—figure supplement 3A). Like the I-SceI-mediated
depletion of wildtype remnants from CRISPR/Cas 3Cs-gRNA constructs, a Bsu36I restriction enzyme
clean-up step removed pLKO.1 wildtype remnants, and SANGER sequencing of the final E2 3Cs-
shRNA library (E2.2) confirmed a randomization of forward- and reverse-complement shRNA
sequences (Figure 3—figure supplement 3B–C). To determine the E2 3Cs-shRNA distribution more
accurately, we performed NGS sequencing with an average shRNA read count of >8,300 and deter-
mined a wildtype remnant level of 0.04%, a CV of 37.9% and an AUC of 0.68, demonstrating an
almost uniform distribution (Figure 3—figure supplement 3D–E). To correlate 3Cs-shRNA abun-
dance and the distribution of the E2 3Cs-shRNA libraries before and after Bsu36I enzyme digest, we
determined the ratios of their respective normalized read counts. Importantly, all ratios were close
to one and lined up close to the respective diagonal with a linear regression R2 of 0.9687 (Figure 3—
figure supplement 5F), demonstrating a high correlation of individual data points and no influence
of the Bsu36I digest on 3Cs-shRNA sequence distribution. In summary, this demonstrates that our
3Cs technology can be adapted to generate high-quality shRNA reagents in single and pooled
formats.
A partially randomized 3Cs gRNA library to target the coding and
noncoding genome simultaneously
The 3Cs method does not require the PCR-amplification of gRNA-encoding oligonucleotides, is free
of conventional cloning steps and uncouples sequence diversity from sequence distribution. Thus,
we hypothesized that 3Cs gRNA library diversity is mostly limited by the number of distinguishable
oligonucleotides within a 3Cs reaction and the subsequent bacterial electroporation efficiencies.
Limitations in electroporation efficiencies can be overcome by accumulating the individual efficien-
cies of multiple parallel reactions, as routinely performed to amplify phage libraries with diversities
beyond 109 (Smith and Scott, 1993). The number of distinguishable oligonucleotides is limited by
the capacity of synthetic oligonucleotide synthesis, rendering truly genome-wide gene perturbation
libraries unfeasible.
Figure 3 continued
Figure supplement 2. 3Cs facilitates the generation of shRNA libraries.
DOI: https://doi.org/10.7554/eLife.42549.008
Figure supplement 3. A 3Cs E2 shRNA library.
DOI: https://doi.org/10.7554/eLife.42549.009
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Previously identified SpCas9 nucleotide preferences included a preference for 30 pyridine bases
whereas thymidine nucleotides are disfavored (Doench et al., 2014; Doench et al., 2016). In an
exploratory effort, we translated SpCas9 gRNA nucleotide preferences into a degenerated oligonu-
cleotide sequence (truly genome-wide, TGW) of 20 nucleotides, representing a theoretical diversity
of 7.3  1010 (Figure 4A) and maximally targeting 1.65  107 sites in the human coding and noncod-
ing genome (Figure 4A and Supplementary file 8). As mentioned above, randomized positions in
DNA oligonucleotides can contain a strong single nucleotide cytosine bias, we therefore used hand-
mixed phosphoramidite pools to generate this oligonucleotide pool. In eight parallel large-scale 3Cs
reactions (each involving 20 mg ssDNA and 600 ng oligonucleotide), we applied this oligonucleotide
to dU-ssDNA of pLentiGuide and pLentiCRISPRv2 and resolved the 3Cs products by gel electropho-
resis (Figure 4B). Importantly, we note that the amplification of this degenerated library is limited by
the number of transformed bacteria. As complete generation of this reagent is currently unfeasible,
we limited our efforts to eight parallel electroporation reactions and achieved a cumulative transfor-
mation efficiency of 1.2  1010, accounting for ~16% of TGW sequences, assuming a stringent uni-
form sequence distribution. In order to approximate the gRNA distribution, we generated 14.4
million NGS reads and found 94.19% to be unique (Figure 4C and Supplementary file 9). We went
on to extract the nucleotide frequencies for each gRNA position from TGW NGS reads, translated
them to IUPAC nomenclature, and identified the identical degenerated sequence that we initially
applied in the form of the degenerated oligonucleotide pool (Figure 4D). Furthermore, the distribu-
tion of TGW read counts had a CV of 0.26% and an AUC of 0.52, suggesting a nearly uniform distri-
bution of sequenced and represented gRNA sequences (Figure 4E–F) (Makowski and Soares,
2003).
The 3Cs technology enables the generation of gRNA libraries with sequence diversities exceed-
ing those that can be captured by coverage-based screenings. Being aware of the coverage limita-
tions, we explored a TGW library screen in the context of a strong positive selection pressure. In
hTERT–RPE1 cells, doxorubicin induces a robust, irreversible and dose-dependent reduction of cell
viability within 4 days (Figure 5—figure supplement 1A). We therefore generated 5.5  108 infec-
tious lentiviral particles of the TGW library and applied them to screen for resistance to doxorubicin
(Figure 5A–B). In three biologically independent experiments, we transduced a total of 5.5  108
hTERT–RPE1 cells with a MOI of 1, added 1 mM doxorubicin 7 d post transduction and replaced the
media every 7 d for 21 consecutive days. Cells that survived the treatment were harvested and their
genomic DNA was extracted for NGS (Figure 5B). Although the experimental reproducibility was
low (0.004%), we identified an experimental overlap of 4,232 gRNAs, with associated Spearman
ranking and Pearson correlations of above 0.75 (Figure 5C and Figure 5—figure supplement 1B).
To validate these sequences, we designed and generated a new 3Cs-gRNA validation library consist-
ing of the identified 4,232 gRNAs and repeated the doxorubicin resistance screen with established
experimental parameters (coverage of 1,000 and MOI of 0.2) (Figure 5—figure supplement 2A–B).
As a result, we reidentified 2,716 gRNAs of which 795 were more than two-fold enriched after 21 d
of doxorubicin treatment when compared to the untreated control (Figure 5D and
Supplementary file 11). In order to map the 795 gRNA sequences to a location within the human
genome, we applied Cas-OFFinder and used the Ensembl, ENCODE, Roadmap Epigenomics and
Blueprint databases for sequence annotation (Bernstein et al., 2010; Dunham et al., 2012;
Ferna´ndez et al., 2016; Zerbino et al., 2018). We identified seven gRNAs to target five genes
(PDE8B, AVPR2, CYSLTR2, IL3RA, and POLE2), of which PDE8B and AVPR2 were targeted by two
gRNAs, and a single gRNA sequence matched a noncoding location within chromosome 8
(chr8:93022800) (Figure 5E and Figure 5G and Supplementary file 12–13). The coding hits that we
identified included CysLTR2, a Leukotriene C4 G-protein-coupled eicosanoid receptor that was
recently reported to induce doxorubicin resistance by abolishing the accumulation of reactive oxy-
gen species (Dvash et al., 2015). To validate CysLTR2 as a doxorubicin-resistance inducing hit, we
chemically inhibited CysLTR2 with increasing concentrations of Bay-CysLT2 or Bay-u9773 in the pres-
ence of doxorubicin and quantified cell viability by AlamarBlue staining. Importantly, both drugs
reverted the doxorubicin-induced toxicity in a dose-dependent manner (Figure 5F), suggesting that
the loss of CysLTR2 causes doxorubicin resistance.
To account for sequence differences between rRNAs from hTERT–RPE1 cells and the reference
genome (GRCh38.86), as well as SpCas9 off-target activity (Cho et al., 2014; Hsu et al., 2013;
Pattanayak et al., 2013), we extended our computational analysis by allowing up to two
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mismatches during Cas-OFFinder-based target sequence identification. As expected, the number of
gRNAs that could be mapped to the reference genome increased to 192 and 222 for coding and
noncoding target sites, respectively, accounting for 50.3% of the 795 gRNAs (Figure 5E and
Supplementary file 12). Interestingly, when mismatches are allowed, we identified three gRNAs
that targeted two different coding positions within the AKAP6 gene (chr14:32671632,
chr14:32784395), as well as five different gRNAs that targeted the exact same coding position within
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Figure 4. A truly genome-wide (TGW) CRISPR/Cas 3Cs-gRNA library to interrogate the coding and noncoding genome. (A) Previously reported SpCas9
nucleotide preferences were translated into a degenerated oligonucleotide sequence (TGW) representing a total sequence diversity of 7.3  1010
(Doench et al., 2014). (B) The TGW oligonucleotide shown in panel (A) was used in a 3Cs reaction on template ssDNA derived from pLentiGuide and
plentiCRISPRv2 plasmids to generate 3Cs-dsDNA, which was analyzed by gel electrophoresis. (C) Scatter plot visualizing TGW library NGS data from
14,448,469 total reads. Displayed are the log10 values of gRNA abundance (reads) against the log10 of the respective percentage of identified TGW
gRNAs. 94.2% of all identified gRNAs were found only once (see also Supplementary file 9). (D) High-throughput sequencing data from panel (C) were
used to compute the nucleotide frequency at each gRNA nucleotide position in order to determine the nucleotide profile of the TGW library. The
identified nucleotide frequencies closely resemble the pattern of the degenerated TGW oligonucleotide from panel (A). Color code represents
nucleotide frequency as indicated by the color gradient on the right. (E) Box plot of TGW gRNA distribution with data derived from panel (C). The
coefficient of variation of 0.26% suggests a uniform distribution of represented sequences. (F) The gRNA distribution of the TGW library as derived
from panel (C) plotted as a Lorenz curve. TGW NGS data derived from pane; (C). The area under the curve (AUC) of 0.52 suggests a uniform
distribution of gRNA sequences.
DOI: https://doi.org/10.7554/eLife.42549.010
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Figure 5. TGW-based identification of coding and noncoding sequences that are associated with doxorubicin resistance. (A) Scheme illustrating the
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hTERT–RPE1 cells were transduced with TGW lentivirus with an MOI of 1, selected with puromycin for 7 days, and treated with 1 mM doxorubicin. After
Figure 5 continued on next page
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the ASPA2 gene (chr2:9229295) (Figure 5E and Supplementary file 12). Within the noncoding
gRNA target sites, we identified four gRNAs that targeted four different positions on chromosome
X (56546543, 57766898, 63133046, 63245878), all of which are in close proximity to the SPIN2A
gene (Figure 5G and Supplementary file 13), suggesting a doxorubicin-tolerance-inducing function
in this locus.
In order to reveal whether the identified set of coding genes correlated with reported pheno-
types or gene ontologies, we performed a molecular signature analysis of the 178 coding target
regions and identified 25 genes that match the UV_RESPONSE_VIA_ERCC3 (downregulated in
mutant ERCC3-expressing fibroblasts) group as the most significant hit (p-value of 6.11E-17)
(Figure 5H–I and Supplementary file 14). Importantly, doxorubicin-induced interstrand crosslinks
are repaired by ERCC3-dependent nucleotide excision repair (NER), and NER-deficient cells have
been shown to display greater tolerance to adduct-forming anthracycline treatment, connecting
these 25 genes to an increased doxorubicin tolerance (Bret et al., 2013; Spencer et al., 2008;
van Brabant et al., 2000). Furthermore, mutations in noncoding sequences have been linked to the
misregulation of adjacently located genes by disrupting cis-regulatory elements (Hnisz et al., 2016;
Katainen et al., 2015; Weinhold et al., 2014). Therefore, we searched for available biotypes
that are associated with the identified noncoding target regions and were able to identify target
sites matching ‘predicted promoter’ (12.6%), ‘lincRNAs’ (11.3%) as well as ‘processed pseudogenes’
(4.5%) and ‘CTCF binding sites’ (3.6%) annotations (Figure 5J and Supplementary file 13). How-
ever, no biotype or genomic annotation was available for 52.7% of the noncoding gRNAs, and we
therefore identified the nearest 50 and 30 located genes and used them to perform a molecular sig-
nature analysis (Figure 5K and Supplementary file 15). Among the four most enriched molecular
signatures, we identified genes that are regulated by the transcription factors FOXO4, KLF1, and
NFAT, noting that FOXO4 and NFAT downregulation has previously been reported to increase
doxorubicin tolerance (Figure 5K and Supplementary file 15).
In summary, we explored the possibility of generating a partially degenerated SpCas9-gRNA
library and its application in positive selection screens. Despite the limitations attributed to the gen-
eration of such a reagent and its applicability in cellular screens, we identified previously known and
Figure 5 continued
three weeks of continuous doxorubicin treatment, all surviving cells were collected and processed for further analysis. (C) Genomic DNA derived from
three independent experiments (n = 3), performed according to the scheme illustrated in panel (B), was used to perform NGS and gRNA sequence
identification. Computational analysis identified an experimental overlap of 4,232 gRNAs (see also Supplementary file 10). (D) A 3Cs library containing
the experimental overlap of 4,232 gRNAs (the validation library) was generated and screened with an experimental coverage of 1,000 and an MOI of 0.1
(similar to the workflow shown in panel (B); see also Figure 5—figure supplement 2). NGS of all surviving cells and computational analysis identified
795 gRNAs that were enriched more than two-fold (orange) when compared to an untreated control. (E) Pie chart visualizing the distribution of coding
target regions with respect to SpCas9 off-target rate (0 to 2 mismatches). A total of 192 gRNAs (22.38% of 795 gRNAs) could be mapped to coding
regions. Color code represents degree of nucleotide mismatch. (F) Chemical inhibition of cells rescued by CysLTR2 from doxorubicin-mediated toxicity.
hTERT–RPE1 cells were treated for 4 d with increasing concentrations of doxorubicin and two chemical inhibitors of CysLTR2 (Bay-CysLT2 and Bay-
u9773) before cellular viability was determined by AlamarBlue assays. Averaged values over three biological replicates (n = 3) in arbitrary units
(AU) are displayed. (G) Pie chart visualizing the distribution of noncoding target regions with respect to SpCas9 off-target rate (0 to 2 mismatches). A
total of 222 gRNAs (27.92% of 795 gRNAs) could be mapped to noncoding regions. Color codingshows the degree of nucleotide mismatch. (H)
Molecular signature analysis of coding gRNA target sites identifies a set of genes that are downregulated in cells expressing mutant forms of ERCC3 as
the top hit. From among the 178-coding gRNA target site-associated genes, 25 genes are part of the ERCC3 group (which has a total of 855 genes)
with high confidence (p=3.7e-17). (I) A list of the 25 ‘down in ERCC3 mutated cells’ genes (light green), as well as their known first- and second-degree
interacting genes (grey), identifies cytokinesis (DOCK1/4 genes) and vesicle transport (SEC24B/TRAPPC8 genes) gene interactions. Interaction data
adapted from String 10.5. (J) Pie chart visualizing the distribution of noncoding gRNA target site annotations, including their frequency (as percentages
of total noncoding hits). Please note: for 52.7% of all noncoding gRNA target sites, no annotation is available. (K) Molecular signature analysis of
noncoding gRNA target sites, using adjacently located genes (one for each, 50 and 30). 33 genes, out of the 211 genes analyzed, are part of the
‘Biosynthetic process’ group (which includes a total of 1,805 genes) with high confidence (p=3.4e-10).
DOI: https://doi.org/10.7554/eLife.42549.011
The following figure supplements are available for figure 5:
Figure supplement 1. Doxorubicin is toxic in hTERT-RPEI cells and TGW replicates correlate.
DOI: https://doi.org/10.7554/eLife.42549.012
Figure supplement 2. Quality control of the TGW validation library.
DOI: https://doi.org/10.7554/eLife.42549.013
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unknown genes that are presumably linked to doxorubicin resistance. In addition, we identified non-
coding sequence regions and their neighboring genes for which gene set enrichment analyses
revealed an enrichment for transcription factors that are connected to increased doxorubicin
tolerance.
An optimized truly genome-wide 3Cs gRNA library
A library’s sequence diversity and distribution directly dictates the experimental scale for positive
and negative selection screens. Therefore, reducing the size of the TGW library to enable coverage-
based screens is highly desirable. In line with this, gRNAs that are truncated to 17 nt have been
demonstrated to maintain on-target efficiencies while reducing off-target effects (Fu et al., 2014;
Wyvekens et al., 2015). We therefore truncated the degenerated TGW oligonucleotide sequence
to 17 nt(optimized TGA, oTGW), approximating to a a total oligonucleotide diversity of 1.5 
109 (Figure 6A). Importantly, the oTGW sequence diversity is 50-times smaller than the TGW
sequence diversity, while the 1.65  107 unique target sequences in the human genome remain
identical (Figure 6A and Supplementary file 8). As for the TGW oligonucleotide, we used hand-
mixed phosphoramidite pools to synthesize the oTGW oligonucleotide and performed 3Cs reactions
by combining this nucleotide with a ssDNA dU-template of the three conventionally used lentiviral
CRISPR/Cas plasmids: pLentiGuide, pLentiCRISPRv2(Puro) and pLentiCRISPR(GFP-Puro). We then
determined successful 3Cs reactions by gel electrophoresis (Figure 6B). Subsequent to bacterial
amplification, an I-SceI clean-up step was performed before the three oTGW libraries were analyzed
by NGS with an average of 28.4 million reads per library (Figure 6C–E and Supplementary file 8).
Importantly, extracted gRNA-position nucleotide frequencies were extracted and translated to
IUPAC nomenclature, revealing the initial oTGW degenerated oligonucleotide sequence (Figure 6F–
H). Furthermore, an average wildtype remnant rate of 0.2% was determined and AUC values were
0.54 or below (Figure 6—figure supplement 1), suggesting a uniform distribution of represented
gRNA sequences in all three oTGW libraries (Makowski and Soares, 2003). Thus, these oTGW
libraries are the first of their kind, have the potential to elevate functional genomics approaches and
will be made available to the scientific community by the Goethe University Depository (http://www.
innovectis.de/INNOVECTIS-Frankfurt/Technologieangebote/Depository).
Discussion
In the present study, we describe the 3Cs technology, an improved Kunkel mutagenesis
protocol that facilitates the one-step and cloning-free generation of high-fidelity CRISPR/Cas and
RNAi gene perturbation reagents. 3Cs uncouples sequence diversity from sequence distribution,
making it useful for the generation of CRISPR/Cas gRNA libraries of arbitrary sequence diversities.
The 3Cs technology has several unique features. First, the bacteriophage-mediated generation of
ssDNA makes the technology applicable to all plasmids containing a f1-origin of replication. Second,
ssDNA-mutagenic oligonucleotides are annealed to the ssDNA of the template DNA, thereby cir-
cumventing the need for two oligonucleotides per gRNA and amplification by PCR, reducing associ-
ated costs and sequence bias. In line with this, T7 DNA polymerase, which is used in the 3Cs
reaction, has an error rate of approximately 15  10 6, resulting in as little as 0.0015% of mutated
heteroduplex 3Cs product assuming 2 mg ssDNA of a 10 kb plasmid (Kong et al., 1993). Third, the
presence of a gRNA placeholder sequence enables the near-complete removal of wildtype plasmid
remnants. Last, we demonstrate 3Cs applicability and performance using the example of lentiviral
plasmids. However, we foresee the plasmid range to be expanded to recombinant Adeno-Associ-
ated Virus (rAAV) plasmids and adenoviruses, as well as coding sequences for protein mutagenesis
that enable in-cell and in-vivo functional screenings.
We demonstrate the fidelity and performance of 3Cs reagents by identifying the proliferative
phenotype of human DUBs, validating previously known and uncovering hitherto unknown DUB phe-
notypes. We show that depletion of the DUBs USP28 and BRCC3 induces positive proliferation phe-
notypes, suggesting that they have tumor suppressive functions. In line with this, USP28 was recently
identified as preventing p53 elevation in response to centrosome loss resulting from Plk4 inhibition,
thereby preventing growth arrest in response to prolonged mitosis (Meitinger et al., 2016). On the
other hand, we identify DUB enzymes whose depletion reduces cell fitness dramatically. Among
them are COPS6 and USP7, both of which have been implicated in DNA damage response and
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Figure 6. Optimized TGW (oTGW) libraries for functional interrogations in the coding and noncoding genome. (A) oTGW oligonucleotide sequence,
based on reported SpCas9 nucleotide preferences. The truncation of three 50 nucleotides results in 17-mer gRNAs with a total oligonucleotide diversity
of 1.5  109. (B) oTGW 3Cs-dsDNA was synthesized on a ssDNA-template of pLentiGuide, pLentiCRISPRv2-Puro and pLentiCRISPRv2-GFP/Puro. 3Cs
products are analyzed by gel electrophoresis on a 0.8% TAE/agarose gel. (C–E) Removal of template plasmid remnants with an I-SceI restriction
enzyme digest. oTGW 3Cs-dsDNA was electroporated with efficiencies above 6.31  109 and amplified for DNA purification (P1). A subsequent I-SceI
Figure 6 continued on next page
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enhanced p53 stability, leading to a prolonged G1-phase cell cycle arrest (Li et al., 2004). In line
with this, recent work demonstrates a direct connection between CRISPR/Cas gene editing and a
p53-dependent DNA damage response that is associated with G1 cell cycle arrest
(Haapaniemi et al., 2018), suggesting that DNA damage-associated DUBs (e.g. COPS6 or USP7)
can be used as p53 alternatives to control for DNA-damage-induced cell cycle arrest and negative
hit calling in CRISPR/Cas functional genomic screens.
CRISPR/Cas functional genomic screens are widely used to interrogate protein-coding regions,
but only few studies have used CRISPR/Cas gene editing to investigate the noncoding genome
(Canver et al., 2015; Diao et al., 2016; Korkmaz et al., 2016; Sanjana et al., 2016). Although
these studies have the potential to open a new area of functional genomics, their general applicabil-
ity is limited to a predefined set of gRNAs and therefore to a small subset of genomic regions. A
unique feature of the 3Cs technology is the uncoupling of gRNA sequence diversity from gRNA
sequence distribution, facilitating the generation of partially randomized gRNA libraries. A fully ran-
domized library with oligonucleotides of length 20 (20N) resembles the entire space of possible
gRNA sequences and comprises 420 = 1.1*1012 different sequences. Although an oligonucleotide
pool covering this huge sequence space could theoretically be synthesized, there are at least two
major reasons that render the experimental application unfeasible. The first reason is that the frac-
tion of gRNA sequences that have a target site in the genome of interest would be very low.
The ~300 million SpCas9 target sites in the human genome would be covered by a fully randomized
library, but would represent only 0.027% of the library. Consequently, the second reason is that the
experimental scale would have to be extremely high to cover all naturally occurring target sites,
including all non-human targeting gRNAs that also need to be included, with sufficient coverage.
Screening the 20N library with a coverage of 100 and a MOI of 0.5 would require 2.2*1014 cells, a
cell number that is clearly not feasible in current experimental setups.
By focusing on SpCas9 nucleotide preferences, we introduce the partially randomized TGW
library, which preferentially targets active gRNA sequences in the entire genome, including both
coding and noncoding regions. The size of the TGW library is dramatically smaller than a fully ran-
domized library but still comprises 7.3*1010 different gRNA sequences. We sought to explore the
experimental application of such a large library and chose to screen for resistance to the cytotoxic
agent doxorubicin in hTERT–RPE1 cells. Although insufficient TGW coverage led to low biological
reproducibility, we were still able to retrieve gRNA overlap of three experiments. We identified pro-
tein-coding genes that have previously been associated with doxorubicin resistance
such as CysLTR2, whose inhibition by two small chemical compounds reverted the doxorubicin-
induced toxicity.
Interestingly, about half of the gRNAs for which we were able to identify a matching sequence in
the human genome map to regions in the noncoding genome. Noncoding mutations have been
shown to play pivotal roles in tumorigenesis by disrupting the function of cis-regulatory elements
(e.g. promoters, enhancer, or transcription- factor binding sites) and topologically associating
domains (TADs), thereby directly affecting the transcriptional regulation of adjacently located genes
(Katainen et al., 2015; Weinhold et al., 2014). We annotated noncoding regions
that are associated with hits from our TGW screen by mapping the corresponding gRNA sequences
against the human reference genome. By allowing up to two mismatches, we attempted to account
not only for exact matches but also for mismatched target sites. This approach yielded a number of
Figure 6 continued
restriction enzyme digest and an electroporation of P1 yielded the final 3Cs libraries containing no detectable template plasmid (P2). An analytical
restriction enzyme digest with I-SceI and EcoRV removes a 2.5-kb DNA fragment from the template plasmid (empty) and to a minor degree from P1
DNA pools. No 2.5-kb fragment could be observed in the final P2 DNA library pools, demonstrating the high purity of the final libraries (see also
Figure 6—figure supplement 1). (F–H) High-throughput sequencing data derived from panels (C–E) were used to compute the nucleotide frequency
of each gRNA nucleotide position, which are visualized as heat maps. The identified nucleotide frequencies closely resemble the pattern of the
degenerated oTGW oligonucleotide shown in panel (A). Color coding illustrates the nucleotide frequencies (0% in blue to 50% in red).
DOI: https://doi.org/10.7554/eLife.42549.014
The following figure supplement is available for figure 6:
Figure supplement 1. oTGW quality control.
DOI: https://doi.org/10.7554/eLife.42549.015
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potential hits that should be interpreted with caution because cut sites might be called incorrectly
and more stringent validation criteria are necessary. Nevertheless, we found a small set of gRNAs
that presumably target predicted promoter sequences as well as CTCF and transcription factor bind-
ing sites, although further validation is necessary to gain mechanistic insights into how these sequen-
ces are linked to doxorubicin resistance.
Furthermore, our computational approach for coding and noncoding hit-calling is sensitive to
incorrect calling of cut sites that can lead to false-positive target regions. We therefore suggest
that the actual genome sequence of the cell line of interest is used in order to limit false-positive hit
calling. We used the human reference genome (GRCh38.86), which might differ from the hTERT–
RPE1 genome, potentially giving misleading conclusions in terms of hit calling. Another strategy to
increase the rate of true-positive hits is to increase library coverage in the experiment. However, it is
currently not feasible to screen either the 20N or the TGW library with sufficient coverage, at least
not in adherent cell lines. To enable coverage-based truly genome-wide screenings, we reduced the
TGW library diversity by truncating the library to 17-mers, yielding optimized TGW (oTGW) libraries
that are more suited for high-throughput experiments with suspension cells. We propose that the
oTGW CRISPR/Cas gRNA libraries are suitable for broad biological screenings with the highest
genetic target complexity. Such screens can be followed by targeted validation screens using newly
synthesized libraries that are tailored to the initially identified cut sites, which will enable rapid func-
tional validation of such complex genetic experiments.
Materials and methods
Key resources table
Reagent type
(species) or
resource Designation Source or reference RRID identifiers
Cell line
(human)
HEK293T ATCC RRID:CVCL_0063
Cell line
(human)
hTERT-RPE1 ATCC RRID:CVCL_4388
Cell line
(human)
RPE1 Ian Cheeseman
Antibody Anti-GFP (B-2) Santa Cruz
Biotechnology
RRID:AB_627695
Antibody Anti-alpha Tubulin DSHB RRID:AB_2315509
Antibody Goat anti-Mouse IgG
(H + L) Secondary Antibody
Thermo Fisher
Scientific
RRID:AB_228307
Antibody Goat anti-Rabbit IgG
(H + L) Secondary Antibody
Thermo Fisher
Scientific
RRID:AB_228341
Bacteria (E. coli) K12 CJ236 NEB (E4141)
Bacteria (E. coli) 10 beta NEB (C3020K)
Recombinant
DNA reagent
pLentiGuide Addgene (52963)
Recombinant
DNA reagent
pLentiCRISPRv2 Addgene (52961)
Recombinant
DNA reagent
PLKO.1 Addgene (8453)
Recombinant
DNA reagent
pPax2 Addgene (12260)
Recombinant
DNA reagent
pMD2.G Addgene (12259)
Commercial kit E.Z.N.A. M13 DNA
Mini Kit
Omega Bio-Tek
(D69001-01)
Commercial kit GeneJET Gel
extraction kit
Thermo Fisher
(K0692)
Continued on next page
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Continued
Reagent type
(species) or
resource Designation Source or reference RRID identifiers
Commercial kit Plasmid Maxi Kit Qiagen (12163)
Commercial kit PureLink Genomic
DNA Mini Kit
Invitrogen
(K1820-01)
Chemical
compound, drug
Ampicillin Roth (K029.2)
Chemical
compound, drug
Chloramphenicol Roth (3886.1)
Chemical
compound, drug
Kanamycin Roth (T832.3)
Chemical
compound, drug
NaCl Roth (31434)
Chemical
compound, drug
ATP NEB (756)
Chemical
compound, drug
DTT Cell Signaling
Technology
Europe (7016)
Chemical
compound, drug
dNTP mix Roth (0178.1/2)
Chemical
compound, drug
Penicillin-streptomycin Sigma-Aldrich
(P4333)
Chemical
compound, drug
Hygromycin Capricorn
Scientific
(HYG-H)
Chemical
compound, drug
Lipofectamin 2000 Thermo
Fisher
(11668019)
Chemical
compound, drug
Polybrene Sigma Aldrich
(H9268)
Chemical
compound, drug
Doxorubicin Selleckchem
(S1208)
Chemical
compound, drug
Bay-CysLT2 Cayman Chemical
(10532)
Chemical
compound, drug
Bay-u9773 Tocris Bioscience
(3138)
Other T4 DNA ligase NEB (M0202)
Other T7 DNA polymerase (unmodified) NEB (M0274)
Other 2 mm electroporation cuvette BTX (45–0125)
Other Gene Pulser electroporation system BioRad (164–2076)
Other I-SceI NEB (R0694)
Other DMEM Thermo Fisher
(41965–039)
Other DMEM/F12 Thermo Fisher
(11320–074)
Other FBS Thermo Fisher
(10270)
Other M13KO7 helper phage NEB (N0315)
Other Polyethylene glycol Roth (263.2)
Other SOC outgrowth medium Thermo Fisher
(15544034)
Other 2YT medium Roth (6676.2)
Other T4 polynucleotide kinase NEB (M0201)
Continued on next page
Wegner et al. eLife 2019;8:e42549. DOI: https://doi.org/10.7554/eLife.42549 18 of 31
Tools and resources Cell Biology Genetics and Genomics
Continued
Reagent type
(species) or
resource Designation Source or reference RRID identifiers
Other T7 endonuclease NEB (M0302)
Other OneTaq DNA polymerase NEB (M0480)
Other Next High-Fidelity 2x PCR Master Mix NEB (M0541)
Other NextSeq 500 Illumina
Software,
algorithm
bcl2fastq Illumina RRID:SCR_015058
Software,
algorithm
cutadapt v.1.15 Martin, 2011 RRID:SCR_011841
Software,
algorithm
CasOFFinder v2.4 Bae et al., 2014
Software,
algorithm
SnpEff 4.3T Cingolani et al., 2012 RRID:SCR_005191
Software,
algorithm
MAGeCK Li et al., 2014
Cloning of 3Cs template plasmids
The NHT and I-SceI gRNA sequences (see ’DNA oligonucleotides’) were annealed and cloned into
pLentiGuide (Addgene 52963) and pLentiCRISPRv2 (Addgene 52961) via BsmBI restriction enzyme
digest (NEB, R0580) and subsequent ligation with T4 ligase (NEB, M0202). Correct clones were iden-
tified by Sanger sequencing at Microsynth SeqLab, Switzerland, using a U6 primer (see ’DNA
oligonucleotides’).
3Cs oligonucleotide design
All of the 3Cs oligonucleotides that were used in experiments are listed in ’DNA oligonucleotides’.
DNA oligonucleotides were purchased from Sigma-Aldrich and Integrated DNA Technologies (IDT)
as single or pooled oligonucleotides, and from Twist Bioscience or CustomArray Inc. as oligonucleo-
tide pools. The 3Cs oligonucleotides were designed with two homology regions flanking the
intended 20-nt gRNA sequence. The homology regions were at least 15 nt in length (Tm above 50˚C)
and matched the 30 end of the U6 promoter region and the 50 start of the gRNA scaffold in the tem-
plate plasmids. The TGW and the oTGW 3Cs oligonucleotides were designed on the basis of a pat-
tern of nucleotide preferences as previously determined (Doench et al., 2014; Doench et al., 2016).
The observed nucleotide preferences were translated into a degenerated 17-nt DNA sequence
(oTGW, see ’DNA oligonucleotides’). The randomized oligonucleotides for the six libraries of
increasing diversity each had stretches of an increasing number of fully randomized nucleotides (see
’DNA oligonucleotides’). The oligonucleotide with four randomized positions was designed to con-
tain the stretch of four consecutive Ns beginning at position 30 of the oligonucleotide. Oligonucleo-
tides with increasing randomization were designed by extending the randomized pattern in an
alternating fashion left and right by one randomized position each. The randomized segments and
the flanking constant regions were designed to replace the I-SceI recognition site in the template
plasmid to enable the clean-up digestion step. In general, every gRNA was designed to avoid
the occurrence of the I-SceI recognition site.
Overview of reagents and equipment needed for the synthesis of 3Cs
Equipment
Desktop microcentrifuge, shaking incubator at 37˚C, 1.5 ml collection tubes, filtered sterile pipette
tips, thermoblocks at 90˚C and 50˚C (e.g., Thermo Fisher, 88870004), an ultracentrifuge capable of
spinning 50 ml falcon tubes at 10,000 rpm (Beckman Coulter Avanti J-30 I ultracentifuge and a Beck-
man JA-12 fixed angle rotor), falcon tubes (polypropylene, 50 ml (Corning 352070)), a Bio-Rad Gene
Pulser electroporation system (BioRad 164–2076), electroporation cuvettes Plus (2 mm, Model no.
620 (BTX)), a gel electrophoresis chamber, and erlenmeyer flasks (glass, 100 ml).
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KCM Transformation
5x KCM buffer (0.5M KCl, 0.15M CaCl2, 0.25M MgCl2), Escherichia coli strain K12 CJ236 (NEB,
E4141), SOC outgrowth medium (ThermoFisher Scientific, 15544034), LB-agar plates supplemented
with 100 mg/ml ampicillin (Roth, K029.2).
Phage amplification and ssDNA purification
2YT media (Roth, 6676.2), M13KO7 helper phage (NEB, N0315), ampicillin (Roth, K029.2), chloram-
phenicol (Roth, 3886.1), kanamycin (Roth, T832.3), uridine (Sigma-Aldrich, U3750), 20% PEG/NaCl
(20% polyethylene glycol (Roth, 0263.2), 2.5 M NaCl (Roth, 31434)), Dulbecco’s phosphate-buffered
saline (PBS, Sigma, D8662), E.Z.N.A. M13 DNA Mini Kit (Omega Bio-Tek, D69001-01), store purified
phage in PBS at 4˚C.
3Cs-DNA synthesis
10x TM buffer (0.1 M MgCl2, 0.5 M Tris-HCl, pH 7.5), 10 mM ATP (NEB, 0756), 100 mM DTT (Cell
Signaling Technology Europe, 7016), T4 polynucleotide kinase (NEB, M0201), 100 mM dNTP mix
(Roth, 0178.1/2), T4 DNA ligase (NEB, M0202), T7 DNA polymerase (unmodified) (NEB, M0274),
Thermo Fisher Scientific GeneJET Gel Extraction Kit (Thermo Fisher, K0692), 3M sodium acetate
(Sigma-Aldrich, 71196).
Electroporation and I-SceI clean-up digest
2 mm cuvette (BTX, 45–0125), electrocompetent E. coli (10-beta, NEB, C3020K), SOC outgrowth
medium (Thermo Fisher, 15544034), LB-media (Roth, X964.3) supplemented with 100 mg/ml ampicil-
lin, Qiagen Plasmid Maxi Kit (Qiagen, 12163), I-SceI (NEB, R0694), NEB CutSmart buffer (NEB,
B7204), 0.5% TAE/agarose gel, Thermo Fisher Scientific GeneJET Gel Extraction Kit.
dU-ssDNA template amplification
Bacteria (Escherichia coli strain K12 CJ236, NEB, E4141) were transformed with 500 ng of template
plasmid according to the following protocol: DNA was mixed with 2 ml of 5x KCM buffer (0.5M KCl,
0.15M CaCl2, 0.25M MgCl2) set to 10 ml with water and chilled on ice for 10 min. An equal volume
of CJ236 bacteria was added to the DNA/KCM mixture, gently mixed, and incubated on ice for 15
min. The bacteria–DNA mixture was then incubated at room temperature for 10 min, and subse-
quently inoculated into 200 ml of prewarmed SOC media (ThermoFisher Scientific, 15544034). Bacte-
ria were incubated at 37˚C and 200 rpm for 1 hr and then selected with ampicillin (100 mg/ml) on LB-
agar plates overnight at 37˚C.
The next morning, a single colony of transformed CJ236 was picked into 1 ml of 2YT media
(Roth, 6676.2) supplemented with M13KO7 helper phage (NEB, N0315) to a final concentration of 1
 108 pfu/ml, chloramphenicol (final concentration 35 mg/ml), and ampicillin (final concentration 100
mg/ml) to maintain the host F0 episome and the phagemid, respectively. Supplementation of uridine
(Sigma-Aldrich, U3750) was set to 2.5 mM. After 2 hr of shaking at 200 rpm and 37˚C, kanamycin was
added to a final concentration of 25 mg/ml to select for bacteria that have been infected with
M13KO7 helper phage. Bacteria were kept at 200 rpm and 37˚C for an additional 6 hr before the
culture was transferred to 30 ml of 2YT media supplemented with ampicillin (final concentration 100
mg/ml) and kanamycin (final concentration 25 mg/ml). After 20 hr of shaking at 200 rpm and 37˚C,
the bacterial culture was centrifuged for 10 min at 10,000 rpm and 4˚C in a Beckman JA-12 fixed
angle rotor. To precipitate phage particles, the supernatant was transferred to 6 ml (1/5 of culture
volume) PEG/NaCl (20% polyethylene glycol 8,000, 2.5 M NaCl), incubated for 1 hr at room temper-
ature and subsequently centrifuged for 10 min at 10,000 rpm and 4˚C in a Beckman JA-12 fixed
angle rotor. The phage pellet was resuspended in 1 ml Dulbecco’s phosphate-buffered saline (PBS,
Sigma, D8662) and centrifuged at 13,000 rpm for 5 min, before the phage-containing supernatant
was stored at 4˚C. Circular ssDNA was purified from the resuspended phages with the E.Z.N.A. M13
DNA Mini Kit (Omega Bio-Tek, D69001-01) according to the manufacturer’s protocol, and purified
ssDNA was stored at 4˚C.
3Cs-DNA synthesis
The oligonucleotides that were used for 3Cs reactions and the suppliers are listed separately (see
’DNA oligonucleotides’). 3Cs oligonucleotides for specific pools were mixed in equimolar ratios. 600
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ng of pooled oligonucleotides were phosphorylated by mixing them with 2 ml 10x TM buffer (0.1 M
MgCl2, 0.5 M Tris-HCl, pH 7.5), 2 ml 10 mM ATP (NEB, 0756), 1 ml 100 mM DTT (Cell Signaling Tech-
nology Europe, 7016), 20 units of T4 polynucleotide kinase (NEB, M0201) and water to a total vol-
ume of 20 ml. The mixture was incubated for 1 hr at 37˚C.
Phosphorylated oligonucleotides were annealed to the circular dU-ssDNA template by adding 20
ml of phosphorylation product to 25 ml 10x TM buffer, 20 mg of dU-ssDNA template, and water to a
total volume of 250 ml. The mixture was denatured for 3 min at 90˚C, annealed for 5 min at 50˚C,
and cooled down for 5 min at room temperature.
3Cs-DNA was generated by adding 10 ml of 10 mM ATP, 10 ml of 100 mM dNTP mix (Roth,
0178.1/2), 15 ml of 100 mM DTT, 2000 ligation units of T4 DNA ligase (NEB, M0202), and 30 units of
T7 DNA polymerase (NEB, M0274) to the annealed oligonucleotide–ssDNA mixture. The 3Cs synthe-
sis mix was incubated for 12 hr (overnight) at room temperature. The 3Cs synthesis product was
then affinity purified and desalted using a Thermo Fisher Scientific GeneJET Gel Extraction Kit
(Thermo Fisher, K0692) according to the following protocol: 600 ml of binding buffer and 5 ml 3M
sodium acetate (Sigma-Aldrich, 71196) were added to the synthesis product, mixed and applied to
two purification columns, which were centrifuged for 3 min at 460 g (2,500 rpm in a Sigma-Aldrich
1–14 table top centrifuge). The flow-through was applied a second time to the same purification col-
umn to maximize yield and centrifuged for 3 min at 460 g. DNA was eluted in 40 ml warm water. The
3Cs reaction product was analyzed by gel electrophoresis alongside the dU-ssDNA template on a
0.8% TAE/agarose gel (100 V, 30 min). 3Cs-shRNA libraries were synthesized according to the proto-
col described above with the following modifications: in two setups, either 60 ng or 120 ng of circu-
lar template dU-ssDNA of pLKO.1 (Addgene: 1864) was used.
Electroporations and I-SceI clean-up digest
To generate pool 1 (P1) of a library, 3Cs-DNA constructs were electroporated with a cold 2 mm
cuvette (BTX, 45–0125) into electrocompetent E. coli (10-beta, NEB, C3020K) using a Bio-Rad Gene
Pulser with the following settings: resistance 200 Ohm, capacity 25 F, voltage 2.5 kV. 2 mg of DNA
was mixed with 400 ml of freshly thawed cells. Electroporated cells were rescued in 25 ml of pre-
warmed SOC media and incubated for 30 min at 37˚C and 200 rpm.
After 30 min of incubation, a dilution series was performed to determine the transformation effi-
ciency and the number of transformed bacteria. 10 ml of culture was diluted 10 1 to 10 12 and
plated on LB agar plates supplemented with 100 mg/ml ampicillin. The remaining culture was added
to 200 ml LB-media (Roth, X964.3) supplemented with 100 mg/ml ampicillin. Plates were incubated
overnight at 37˚C, the liquid cultures were incubated overnight at 37˚C and 200 rpm. The next day,
the electroporation efficiency and the number of transformed bacteria were determined.
The plasmid DNA of the overnight liquid cultures was purified using a Qiagen Plasmid Maxi Kit (Qia-
gen, 12163) according to the manufacturer’s protocol.
To generate the final pool 2 (P2) of a library, 10 mg of purified P1 DNA was digested with 50 units
I-SceI (NEB, R0694) and 5 ml NEB CutSmart buffer (NEB, B7204) in a reaction volume of 50 ml for 1.5
hr at 37˚C. The digestion reaction was subjected to gel electrophoresis on a 0.5% TAE/agarose gel
(100 V, 30 min) to separate the undigested 3Cs synthesis product from linearized template plasmid.
The band resembling the undigested correct 3Cs synthesis product was purified using a Thermo
Fisher Scientific GeneJET Gel Extraction Kit according to the manufacturer’s protocol. In a second
step, the purified 3Cs synthesis product was electroporated according to the electroporation proto-
col described above. The final P2 library preparation was purified from liquid culture using a Qiagen
Plasmid Maxi Kit according to the manufacturer’s protocol and quality controlled with analytical
restriction enzyme digests. 3Cs-shRNA pools were generated according to the above protocol with
the following modifications. Instead of using I-SceI for the clean-up digestion, we used Bsu36I to
digest template plasmid remnants in the first DNA pool (P1). P1 was electroporated using the set-
tings described above to yield the final pool (P2). Both 3Cs-shRNA pools were purified from liquid
culture using a Qiagen Plasmid Maxi Kit according to the manufacturer’s protocol and were quality
controlled with analytical restriction enzyme digests and Sanger sequencing.
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Cell culture
HEK293T cells (ATCC, CRL-3216) were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM,
Thermo Fisher Scientific, 41965–039) and hTERT–RPE1 cells (ATCC, CRL-4000 and Ian Cheeseman’s)
in DMEM: Nutrient Mixture F-12 (DMEM/F12, Thermo Fisher Scientific, 11320–074), each supple-
mented with 10% fetal bovine serum (FBS, Thermo Fisher Scientific, 10270) and 1% penicillin-strep-
tomycin (Sigma-Aldrich, P4333) at 37˚C with 5% CO2. In addition, hTERT–RPE1 cells were
supplemented with 0.01 mg/ml hygromycin B (Capricorn Scientific, HYG-H). hTERT–RPE1 cells were
obtained from ATCC/LGC (CRL-4000) and Ian Cheeseman. No method to ensure the state of
authentication has been applied. Mycoplasma contamination testing was performed immediately
after the arrival of the cells and multiple times during the course of the experiments.
Cell extracts and antibodies
Preparation of lysates and immunoblot analyses were performed as described previously using Tris
lysis buffer (50 mM Tris–HCl (pH 7.8), 150 mM NaCl, 1% IGEPAL CA-630) containing 20 mM NaF, 20
mM b-glycerophosphate, 0.3 mM Na-vanadate, 20 mg/ml RNase A, 20 mg/ml DNase and 1/300 pro-
tease inhibitor cocktail (Sigma-Aldrich, P8340) and phosphatase inhibitor cocktail #2 (Sigma-Aldrich,
P5726) (Kaulich et al., 2015). The antibodies used in this study were purchased from the following
sources: mouse anti-GFP (GFP (B-2): sc-9996, 1:2,000, Santa Cruz Biotechnology, Inc.), mouse anti-
Tubulin (clone 12G10, 1:1,000, Developmental Studies Hybridoma Bank, University of Iowa). Second-
ary antibodies used for western blot analysis were goat anti-mouse (Thermo Scientific, 31430) and
goat anti-rabbit (Thermo Scientific, 31460). The mouse anti-Tubulin hybridoma cell line (clone
#12G10) was developed by J. Frankel and E.M. Nelson under the auspices of the NICHD and main-
tained by the Developmental Studies Hybridoma Bank. Protein levels were visualized with Pierce
ECL Western Blotting Substrate on a BioRad ChemiDoc MP imaging system and analyzed with Bio-
Rad Image Lab software (version 4.1 build 16).
Generation and quantification of lentiviral particles
The day before transfection, HEK293T cells were seeded to 5  105 cells/ml. To transfect HEK293T
cells, transfection media containing 1/10 of culture volume Opti-MEM I (Thermo Fisher Scientific,
31985–047), 10.5 ml Lipofectamin 2000 (Thermo Fisher Scientific, 11668019), 1.65 mg/ml transfer vec-
tor, 1.35 mg/ml pPAX2 (Addgene, 12260) and 0.5/ml mg pMD2.G (Addgene, 12259) was prepared.
The mixture was incubated for 30 min at room temperature and added drop-wise to the media. The
next morning, the transfection medium was replaced with fresh media to remove the transfection
reagent. Lentiviral supernatant was harvested at 24 hr and 48 hr after transfection, pooled and
stored at  80˚C.
To determine the lentiviral titer, hTERT–RPE1 cells were plated in a 24-well plate with 20,000 cells
per well. The following day, cells were transduced using 8 mg/ml polybrene (Sigma, H9268) and a
series of 0.5, 1, 5, and 10 ml of viral supernatant. After 3 days of incubation at 37˚C, the percentage
of fluorescence-positive cells was determined by flow cytometry. The following formula was used to
calculate the viral titer: Virustiter transducing units=mLð Þ ¼
20:000 target cells%of GFP positive cells
100
volume of supernatant mLð Þ .
Alternatively, lentiviral titers were determined by colony formation titering assay for lentivirus.
Flow cytometry
All samples were analyzed on a FACSCanto II flow cytometer (BD Biosciences), and data were proc-
essed by FlowJo software (FlowJo, LLC). Gating was carried out on the basis of viable and single
cells that were identified on the basis of their scatter morphology.
Lentiviral transduction
hTERT–RPE1 cells were seeded at an appropriate density for each experiment with a maximal conflu-
ency of 60–70% in DMEM/F12, supplemented with 10% FBS, 0.02 mg/ml hygromycin, and 1% peni-
cillin-streptomycin. On the day of transduction, polybrene was added to the media to a final
concentration of 8 mg/ml. The volume of lentiviral supernatant was calculated on the basis of the
diversity of the respective library and of the desired coverage and multiplicity of infection (MOI) of
the experiment. The number of cells that were transduced at the beginning of an experiment was
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calculated by multiplying the diversity of the library with the desired coverage and the desired MOI.
For example, the parameters for the DUB library screen were set at a coverage of 1.000 and an MOI
of 0.2, that is one lentiviral particle per five cells. The total number of cells that were transduced was
calculated as follows: 363 * 1,000 * 5 = 1,815,000. The next morning, the medium was replaced with
fresh media and the cells were subjected to antibiotic selection or experimental analysis.
Homology arm lengths and 3Cs reaction times
To test different homology arm lengths, four 3Cs reactions were performed using four different oli-
gonucleotides with increasing lengths of homology to the pLentiGuide NHT, according to the 3Cs
synthesis protocol described above. The reaction products were analyzed by gel electrophoresis.
To monitor the 3Cs synthesis process over time, we annealed the TGW oligonucleotide to the
pLentiGuide NHT and generated 3Cs-dsDNA. 2 ml of the reaction was sampled from the reaction
tube and transferred to  20˚C at different timepoints from 0 hr to 20 hr. All samples were analyzed
together by agarose gel electrophoresis. To visualize the kinetics of the 3Cs reactions, 3Cs-dsDNA
band intensities were determined and normalized to time point 0 before plotting against the time of
their harvest using the Bio-Rad Image Lab software (version 4.1 build 16).
eGFP gene editing and T7 endonuclease I assay
The efficiency of eGFP gene editing was analyzed by transducing eGFP-expressing hTERT–RPE1
cells with 3Cs gRNA constructs based on pLentiCRISPRv2, a subsequent T7 Endonuclease I assay,
and immunoblotting. The experiment was performed in triplicates using a control gRNA (NHT), a sin-
gle GFP-targeting 3Cs-gRNA (GFP#1) or a pool of six GFP-targeting 3Cs-gRNAs (GFP#1–6). After
7 d of incubation at 37˚C without antibiotic selection, cells were trypsinized and the genomic DNA
was purified using a PureLink Genomic DNA Mini Kit (Invitrogen, K1820-01) according to the manu-
facturer’s protocol.
To assess the genome targeting efficiency of the 3Cs reagents, we analyzed the four cell popula-
tions that were transduced with the NHT-gRNA, the GFP#1 gRNA or the GFP#1–6 pool, or
that were not transduced at all. We PCR-amplified the GFP locus with OneTaq DNA polymerase
(NEB, M0480) using 1 mg of genomic DNA, 40 mM dNTPs (final concentration), 0.2 mM of each for-
ward and reverse amplification primer (see ’DNA oligonucleotides: eGFP T7 forward and eGFP T7
reverse’), 10x OneTaq standard buffer, and 2.5 units of OneTaq DNA polymerase. The cycles were
set up as follows: initial denaturation at 94˚C for 3 min, 39 cycles of denaturation at 94˚C for 20 s,
annealing at 55˚C for 30 s, strand extension at 68˚C for 2 min, and final strand extension at 68˚C for
5 min. The PCR products were analyzed on a 0.8% TAE/agarose gel (100 V, 30 min) and purified
using a Thermo Fisher Scientific GeneJET Gel Extraction Kit according to the manufacturer’s proto-
col. The T7 endonuclease I digestion was assembled with 6 mg of purified PCR product, 10x NEBu-
ffer 2 water to 48 ml, denatured at 95˚C for 5 min, and annealed in two steps from 95–85˚C with  2
˚C/second, and from 85–25˚C with  0.1 ˚C/second. To the annealed PCR product, 7 ml of T7 Endo-
nuclease I (NEB, M0302) was added and incubated for 15 min at 37˚C. The fragmented PCR prod-
ucts were analyzed on a 0.8% TAE/agarose gel (100 V, 30 min) and band intensities were
determined using the Bio-Rad Image Lab software (version 4.1 build 16).
DUB proliferation screen
The DUB proliferation screen was performed in biological duplicates. hTERT–RPE1 cells were trans-
duced with lentiviral supernatant with a MOI of 0.2 and a library coverage of 1,000. For each repli-
cate and time point, 2.5 million cells were seeded. Cells corresponding to the control time point
were harvested 2 d post-transduction. All remaining cells were kept in growing and library-diversity-
maintaining conditions in the presence of 10 mg/ml puromycin. After 11 d and 21 d, cells were har-
vested and their genomic DNA purified and processed for NGS. Validation of DUB screen hit candi-
dates was performed in hTERT–RPE1 cells with 3Cs-shRNA-mediated target gene knockdown and
the subsequent assessment of cell proliferation used an AlamarBlue assay (Bio-Rad, BUF012A).
Doxorubicin-resistance-screen hTERT–RPE1 cells were treated with increasing concentrations of
doxorubicin, ranging from 0 to 1,000 nM, for four consecutive days. After 4 d, the treatment was
stopped by changing the medium to doxorubicin-free medium and cells were cultivated for another
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4 d. After a total of 8 d, cell viability was determined and quantified with an AlamarBlue assay (Bio-
Rad, BUF012A).
To screen for doxorubicin resistance, the TGW library was delivered in triplicates to a total of 5.5
 108 hTERT–RPE1 cells with doxycycline-inducible Cas9 expression via lentiviral transduction at a
MOI of 1. Transduced cells were cultured for 7 d in standard medium supplemented with 1 mM doxy-
cycline (Sigma-Aldrich) and 10 mg/ml puromycin. At day 7, the medium was changed to selection
medium containing 1 mM doxorubicin (Selleckchem, S1208). After 3 wk of selection (fresh doxorubi-
cin every 4 d), surviving cells were harvested and processed for NGS.
NGS of plasmid and genomic DNA
To purify genomic DNA, surviving cells were trypsinized and pelleted. Genomic DNA was extracted
using the PureLink Genomic DNA Mini Kit according to the manufacturer’s protocol. For NGS library
preparation, 100 ng of plasmid or up to 2 mg of genomic DNA per reaction was used in a 50 ml PCR
reaction using Next High-Fidelity 2x PCR Master Mix (NEB, M0541) (according to the manufacturer’s
protocol) and 1 ml of 10 mM primers each of forward and reverse primers. Primer sequences are
listed separately (see ’DNA oligonucleotides’). The sequencing primers contained an 8-nt long bar-
code sequence, enabling the multiplexing of several samples in a single sequencing run and Illumina
adapter sequences. Thermal cycler parameters were set as follows: initial denaturation at 98˚C for 5
min, 19 cycles of denaturation at 98˚C for 30 s, annealing at 55˚C for 30 s, extension at 72˚C for 1
min, and final extension at 72˚C for 5 min. PCR products were purified from a 0.5% TAE/agarose gel
using a Thermo Fisher Scientific GeneJet Gel Extraction Kit according to the manufacturer’s proto-
col. The purified PCR product was prepared to a final concentration of 2.4 pM in a total volume of
2.2 ml and loaded onto a NextSeq 500 sequencer (Illumina), according to the manufacturer’s proto-
col. Sequencing was performed with single end reads, 75 cycles and 8 cycles of single index reading.
Data processing and analysis
All data obtained from NGS were demultiplexed using the Illumina command line tool bcl2fastq,
v2.17. gRNA representation of all libraries was assessed using cutadapt v1.15 (Martin, 2011) and
custom Python scripts. In brief, 30 sequencing adapters were trimmed using a prefix of the 30 homol-
ogy sequence; trimmed reads were further trimmed by keeping only the last 20 nucleotides for all
libraries except the oTGW, for which the last 17 nt were kept. Only reads with no ambiguously
sequenced nucleotides were considered for further analyses. For the TGW and the oTGW, the result-
ing sequences were compared to the TGW or oTGW DNA sequence pattern, respectively, using
Python and regular expressions. The reads obtained from sequencing the six randomized libraries
with diversities ranging from 256 to 262,144 gRNAs were processed similarly by comparing the
trimmed reads with the gRNA pattern of the respective library. For the GFP and DUB libraries, the
reads were aligned to the respective sequence library. Matching sequences were counted to deter-
mine the read count distribution of a sample. The read counts of individual gRNAs for a sample
were normalized by the total number of read counts that could be assigned to the respective library.
The screening of samples after treatment of the cells was carried out in the same way. To determine
the dispersion of the read counts, the coefficient of variation was computed by dividing the standard
deviation of the normalized read counts by the mean of the normalized read count x, CV ¼ s
x
. To
assess the uniformity of each library distribution, we generated Lorenz curves of gRNA representa-
tion. The Lorenz curves of gRNA representation rank gRNAs by abundance scaled to 1 and show the
fraction of total sequencing reads that are represented by the sum of gRNA read counts. The area
under the curve (AUC) was computed in GraphPad Prism 5.0b for Mac (GraphPad Software, La Jolla
California USA, www.graphpad.com) or with a custom Python script using Numpy 1.14.2 (Oli-
phant, 2010). Heat maps were generated by accumulating the nucleotide frequency at each position
of the sequenced reads and normalized by the total number of read counts.
To correct the read counts of the six randomized libraries with diversities ranging between 256
and 262,144 gRNAs for C bias, we determined the nucleotide frequencies for each sequence posi-
tion of the trimmed and final reads and normalized the observed frequencies to the expected nucle-
otide frequency of 25%. Each read was then scored by summing the normalized frequencies for all
reads individually. The observed read count per gRNA was then multiplied with this score, divided
by the sum of all read counts that matched the respective gRNA pattern, and normalized to the sum
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of all corrected and normalized read counts. Lorenz curves were generated on the basis of the cor-
rected and normalized read counts.
Read count data from the DUB screen were analyzed by summing all individual gRNA read counts
per gene and normalizing each gene read count per sample to the total number of read counts
within that sample. Spearman correlation and Shapiro-Wilk confidence tests were performed to
assess the reproducibility of the DUB screen replicates. MAGeCK and PinAPL-Py were used to ana-
lyze the read counts of both replicates and to calculate aggregated positive and negative prolifera-
tion phenotypes by means of log2 fold changes with associated p-values.
Analysis of gRNA on- and off-target locations
To determine the on- and off-targets of the 4232 hits from the doxorubicin resistance screen, Cas-
OFFinder (v2.4) was applied to search the human genome (GRCh38.86) for gRNA target sites with
up to two mismatches (Bae et al., 2014). The genomic positions of each on- and off-target were
annotated with Ensembl genome assembly GRCh38.86, using SnpEff 4.3T (Cingolani et al., 2012)
and custom Python scripts. Multiple annotations for a location were collapsed onto a single gene
type and the corresponding gene name, if available. Genomic locations associated with an inter-
genic region were not considered to be annotated. Additional noncoding, regulatory, and pseudo-
gene information was annotated using the Ensembl regulatory and motif features from release 91
and the Gencode consensus pseudogenes dataset from release 27 (GRCh38.p10). Additional stan-
dard annotation data from Gencode, release 27, were also included. Spearman rank and Pearson
correlation were computed with NumPy (1.14.2). To determine the putative effect of gRNA off-tar-
gets on previously identified on-target locations, we mapped the gene names that were associated
with off-targets back to the genes that were associated with on-target hits.
Validation of TGW doxorubicin-resistance screening hits
To validate CysLTR2 as a doxorubicin-resistance-inducing gene, we applied the CysLT2 receptor
antagonists Bay-CysLT2 (Cayman Chemical, 10532) and Bay-u9773 (Tocris Bioscience, 3138). In two
different triplicates, cells were treated with with increasing concentrations (0 mM, 0.01 mM, 0.05 mM,
0.1 mM, 0.25 mM, 0.5 mM, 0.5 mM, 1 mM) of each inhibitor as well as with increasing doxorubicin con-
centrations (0 mM, 1 mM, and 10 mM). After 4 d, cell survival was assessed with an AlamarBlue assay.
10% AlamarBlue was added to the cultured cells and incubated for 2 hr at 37˚C, and fluorescence
was measured with an excitation wavelength of 560 nm and a fluorescence emission of 590 nm on a
BioTek Synergy H1 microplate reader. The given measured fluorescence emissions were averaged
over all replications for each experiment.
The 4,232 hits that were found in the TGW doxorubicin screen were compiled into an individual
3Cs library (validation library). The validation library was generated according to the 3Cs DNA syn-
thesis protocol described above. We seeded 1  106 hTERT–RPE1 in T175 cell culture flasks in
DMEM/F12 and transduced them the next day with lentivirus of the validation library using 8 mg/ml
polybrene with an MOI of 0.1 and an experimental coverage of 1,000. After 3 d, the control cells
were harvested. The screen was conducted with 2.5 mg/ml (final concentration) puromycin selection
and 1 mM doxorubicin treatment. The medium was changed every third day to maintain constant
puromycin and doxorubicin concentrations. After three weeks of selection, surviving cells were har-
vested and processed for NGS according to the procedures described above.
Molecular signatures of coding and noncoding hits
Hits for targets with zero, one and two mismatches were merged and divided in two subsets accord-
ing to the annotation, consisting of protein coding hits and noncoding hits, respectively. For the
coding hits gene set, a set of 159 non-redundant genes was created from all hits with target sites in
protein-coding genes. The frequency of each gene was determined. For the remaining hits, the five
closest genes upstream and the five closest genes downstream of the target site were determined
using GRCh.93 Ensembl gene data. The starting position of a gene and the starting position of a tar-
get site was taken as measure for proximity. A noncoding-hits gene set of 1,805 non-redundant
genes was created and the frequency of each gene was determined. Overlaps between both gene
sets and all gene sets in the Molecular Signatures Database (MSigDB) were computed using
the MiSigDB Web Application to Investigate Gene Sets with a FDR q-value below 0.05
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(Subramanian et al., 2005; Liberzon et al., 2011), Heatmaps with the top four overlapping gene
sets were created using the resulting Excel tables (Figure 5H, Supplementary files 13–14 and the
Python visualization library seaborn 0.9.0 (Waskom et al., 2014).To collect interaction data, we
searched the 25 genes that were associated with ’down in ERCC3 mutated cells’ in the String 10.5
database by choosing up to five interactors in the first and second shell (Szklarczyk et al., 2017)
(Figure 5I).
Data availability
NGS data are provided as raw read count tables as Supplementary files 1, and 17–23. Please note,
raw read count tables associated with TGW and the three oTGW libraries are available from Dryad,
https://doi.org/10.5061/dryad.rs432pr. Plasmids encoding oTGW 3Cs-gRNA libraries will be avail-
able through the Goethe University Depository (http://www.innovectis.de/INNOVECTIS-Frankfurt/
Technologieangebote/Depository).
Code availability
Custom software is publicly available from GitHuB, https://github.com/GEG-IBC2/3Cs (GEG-
IBC2, 2019; copy archived at https://github.com/elifesciences-publications/3Cs).
DNA oligonucleotides
DNA oligonucleotides were purchased from Sigma-Aldrich and Integrated DNA Technologies (IDT)
as single or pooled oligonucleotides, and from Twist Bioscience or CustomArray Inc. as oligonucleo-
tide pools. A detailed list of all oligonucleotides can be found as supplementary information
(Supplementary file 16).
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